natgillin/translations-raw huggingface dataset:
The medicament or the pharmaceutical composition according to claim 15 for treating Graft versus host disease and transplant rejection, wherein the administration to said subject of an effective amount of the medicament or the pharmaceutical composition is in combination with one or more therapeutic agent selected in the group of Calcineurins inhibitors, mTOR inhibitors, anti-proliferative agents, monoclonal antibodies directed to CD25 or anti-thymocyte and antilymphocyte globulin preparations. 
Lijek ili farmaceutski pripravak prema zahtjevu 15 za liječenje reakcija transplantata protiv primatelja (GVHD) i odbijanja presatka, naznačeni time da se efikasna količina lijeka ili farmaceutskog pripravka daje subjektu u kombinaciji s jednim ili više terapijskih agensa iz skupine inhibitora kalcineurina, inhibitora mTOR-a, antiproliferativnih agensa, monoklonalnih antitijela koja djeluju na CD25 ili antitimocit i antilimfocit globulinskih preparata.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183 for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein it is to be administered in a form of a tablet. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku tablete.
delivering oxygen or carbon monoxide to tissues; 
(i) opskrbi tkiva kisikom ili ugljičnim monoksidom;
X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; 
X predstavlja dva atoma vodika, atom sumpora, atom kisika ili C,.» alkilnu skupinu i atom vodika;
under suitable oxime formation conditions to form the compound of formula 4-i. 
ši reakcijom spoja formule 4-i: pod pogodnim uvjetima stvaranja klorooksima.
Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc. 
Bilo koji odgovarajući aditiv koji se obično koristi u struci može se dodati kao što su to tonički agensi, konzervansi, antioksidanti itd.
a DNA-targeting RNA comprising: a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and 
(i) segment koji cilja na DNK 1 koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK, i
A method of preventing or reducing aggregation of Enteroviral particles during purification of the Enteroviral particles from a medium, the method comprising adding to a composition comprising Enteroviral particles a basic amino acid or derivative thereof selected from the group consisting of arginine, lysine, histidine, arginine-HCl, lysine-HCl, histidine-HCl, agmatine, L-arginine ethyl ester dihydrochloride, tranexamic acid, DL-5-hydroxylysine hydrochloride, L-lysine methyl ester dihydrochloride, 3-methyl-L-histidine, salts thereof and combinations thereof, wherein during at least a part of the purification the basic amino acid or a derivative thereof is present at a concentration between 0.5-1000 mM to prevent or reduce aggregation of the viral component. 
Upotreba bazne aminokiseline ili njezinog derivata za sprječavanje ili smanjenje agregacije enterovirusnih čestica tijekom pročišćavanja enterovirusnih čestica iz medija, pri čemu je tijekom bar jednog dijela pročišćavanja bazna aminokiselina ili njezin derivat prisutan u finalnoj koncentraciji od najmanje 1 mM, i dovoljan je da spriječi 1li smanji agregaciju enterovirusnih čestica, 1 pri čemu je bazna aminokiselina ili njezin derivat izabran iz grupe koja se sastoji od: arginina, lizina, histidina, arginina-HCI, lizina-HCI, histidina-HCI, agmatina, dihidroklorida etil estera L-arginina, traneksaminske kiseline, hidroklorida DL-5-hidroksilizina, dihidroklorida metil estera L-lizina, 3-metil-L-histidina, njihovih soli i njihovih kombinacija.
Both the control and the treated groups were studied for 12 weeks. 
Obje skupine, kontrolna i liječena skupina proučavane su 12 tjedana.
The apparatus 1 may therefore also be connected to the INTERNET by way of the network port 11 and/or the modem 12 
Ovaj uređaj 1 može stoga biti također spojen na INTERNET uz pomoć priključka na mrežu 11 i/ili pomoću modema 12.
A method of modifying a polypeptide associated with a target DNA, the method comprising contacting the target DNA with a complex comprising: 
Postupak moduliranja polipeptida koji je povezan s ciljanom DNK, naznačen time, da postupak obuhvaća stavljanje u doticaj ciljane DNK s kompleksom koji obuhvaća sljedeće:
The range within which HA is applicable in the human therapy - beyond those mentioned above - can be widened by modifying the structure chemically. 
Raspon unutar kojeg je HA primjenjiv u terapiranju ljudi - osim ovih već prije spomenutih - može se proširiti kemijskim modificiranjem strukture.
In other words, the capacity to interact and to link (to bind) polar derivatives of unsaturated compounds, particularly oxidation polar derivatives and mainly of oligomeric and polymeric type, with inorganic substrates —typically represented by silicon and aluminium derivatives—allows to obtain a composition which is unexpectedly free of noxious by-products. 
Drugim riječima, kapacitet interakcije 1 povezivanja (vezanja) polarnih derivata nezasićenih spojeva, naročito oksidacijskih polarnih derivata i uglavnom oligomernog i polimernog tipa, s anorganskim supstratima - tipično predstavljenim sa derivatima silicija - omogućava dobivanje pripravka koji je neočekivano oslobođen od štetnih nusprodukata.
EXAMPLE 6 Preparation of the mixture of bitumen 
Broj objave europskog patenta:
Method according to any one of the preceding claims, characterized in that prior to 2-((1-methylpropyl)amino)ethanol addition, said suspension has a temperature of between 5 and 100°C, preferably of between 35 and 85°C, and more preferably of between 45 and 75°C. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je prije dodavanja 2- ((1-metilpropiljaminojetanola, navedena otopina temperature između 5 1 100%C, poželjno između 35 1 85*C, poželjnije između 45 1 75*C.
identifying the peptide of which CTL inducibility is the same as or higher than the one of a peptide consisting of the original amino acid sequence. 
(v) identificiranja peptida čija je CTL inducibilnost ista kao ili veća nego za peptid koji se sastoji od izvornog aminokiselinskog slijeda,
The liquefied gas treatment method according to claim 1, wherein BOG, which is not supplied as fuel to the main engine and the sub engine among BOG compressed by the compressor, is liquefied by exchanging heat with BOG that is discharged from the cargo tank and transferred to the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor uključuje prvi kompresor (13a) i drugi kompresor (13b), gdje se prva struja se grana u drugu struju i treću struju nakon prolaska kroz prvi kompresor.
at least 90 mole percent terephthalic acid residues, based on the total amount of dicarboxylic acid residues in the one or more polyethylene terephthalate homopolymers or copolymers comprising 100 mole percent; and 
(i) najmanje 90 molarnih postotaka ostataka tereftalne kiseline, prema ukupnoj količini ostataka dikarboksilnih kiselina u jednom ili više homopolimera ili kopolimera polietilen-tereftalata koji sadrže 100 molarnih postotaka; i
The compound of claim 1 wherein R3 is H. 
Spoj prema patentnom zahtjevu 1 naznačen time što je R3 jednako H.
A fusion protein comprising an isolated polypeptide, of an amino acid sequence according to SEQ ID NO:148, joined to a heterologous sequence. 
Fuzijski protein prema najmanje jednom od patentnih zahtjeva 11 do 14, naznačen time da ima sekvencu kao što je navedeno u SEQ ID NO: 105.
The present invention provides a fully human anti-VAP-1 antibody heavy chain comprising at least one CDR consensus sequence selected form the group consisting of: 
Ekspresijski vektor koji kodira antitijelo prema zahtjevu 1, koji sadrži sekvencu nukleinskih kiselina izabranu iz skupine koja se sastoji od: i)
said monoclonal antibody is the monoclonal anti idiotypic anti-CA MEN 2234 comprising the SEQ.ID NO.1 and SEQ. 
navedeno monoklonsko antitijelo je monoklonsko antiidiotipsko anti-CA-125 MEN 2234 antitijelo koje uključuje SEQ.
Protocol for Study A: Determination of Blood Glucose Effect in Streptozotocin-Treated Diabetic Rats 
I. Protokol za studiju A: Određivanje efekta glukoze u krvi kod štakora sa dijabetesom tretiranih streptozotocinom
insoluble whey protein particles having a particle size in the range of 1-10 micrometers, where the amount of said insoluble whey protein particles is in the range of 50-100% (w/w) relative to the total amount of protein of the denatured whey protein composition, 
gdje netopljive čestice proteina sirutke imaju veličinu čestica u rasponu od 1-10 um, gdje je količina netopljivih čestica navedenog proteina sirutke u rasponu od 50-100 % (tež./tež.) u odnosu na ukupnu količinu proteina u pripravku denaturiranog proteina sirutke, -
The process of claim 1, wherein the amination reaction is carried out in the presence of a sulfonyl compound. 
Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo u koraku vic, neprotonsko otapalo.
In one embodiment, the compound as defined herein is for use in the prophylaxis or treatment of cancer mediated by FGFR kinases. 
(xi) uporaba u liječenju karcinoma, gdje je karcinom karcinom mokraćnog mjehura s točkastom mutacijom FGFR3; ili
A transdermal delivery device comprising: a polymer matrix layer comprising an opioid agonist with intermixed microspheres comprising opioid antagonist, wherein the opioid antagonist is non-releasable when the transdermal delivery device is applied topically and intact, and wherein the microspheres are in a mean size of from 1 to 300 µm in diameter. 
PATENTNI ZAHTJEVI Uređaj za transdermalnu dostavu koji sadrži: sloj polimerne matrice koji sadrži opioid agonist sa umiješanim mikrosferama koje sadrže opioid antagonist, pri čemu se opioid-antagonist ne može ispustiti kad se uređaj za transdermalnu dostavu primjenjuje lokalno 1 čitav je, te pri čemu mikrosfere imaju srednju veličinu od 1 do 300 pm u promjeru.
Cy1 is optionally further substituted by one to three independent occurrences of R6, wherein each occurrence of R6 is independently selected from —ORB, C1-3aliphatic, or halo. 
Cy' je izborno dalje supstituiran sa jednim do tri nezavisna R*, pri čemu je svako R" nezavisno izabran od -OR?, CL alifatika ili halo. 14.
The intravaginal ring of claim 1, wherein the pharmaceutically acceptable hydrocarbon or glycerol ester of a fatty acid is selected from mineral oil, silicone oil and combinations thereof. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da su farmaceutski prihvatljiv ugljikovodik ili glicerolni esteri masnih kiselina prisutni u koncentraciji od 0,1 % do 10 % ukupne mase prstena.
The oral formulation of embodiment 9, wherein the formulation is in the form of a tablet, and wherein the tablet consists essentially of: 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 1, naznačena time što tableta dodatno sadrži stabilizator.
These compounds could also be used for treatment of catabolism in connection with pulmonary dysfunction and ventilator dependency; treatment of cardiac dysfunction (e.g., associated with valvular disease, myocardial infarction, cardiac hypertrophy or congestive heart failure); and improvement of the overall pulmonary function; transplant rejection; rheumatoid arthritis; multiple sclerosis; inflammatory bowel disease; lupus; graft vs. host disease; T-cell mediated hypersensitivity disease; psoriasis; asthma; Hashimoto's thyroiditis; Guillain-Barre syndrome; cancer; contact dermatitis; allergic rhinitis; and ischemic or reperfusion injury. 
Ovi se spojevi također mogu upotrijebiti za liječenje katabolizma u vezi sa plućnom disfunkcijom i funkcijom disanja; liječenje srčane disfunkcije (npr. povezano sa valvularnom bolešću, miokardijalnim infarktom, srčanom hipertrofijom ili kongestivnim zatajivanjem srca); i poboljšanje ukupne plućne funkcije; odbacivanje transplanta, reumatski artritis, multiple skleroza, upalna bolest crijeva, lupus, bolesti odbacivanja transplanta, hipersenzitivne bolesti posredovane T-stanicama, psorijaza, astma, Hashimotov tiroiditis, Guillain-Barreov sindrom, rak, kontaktni dermatitis, alergijski rinitis i ishemija ili nemogućnost zacjeljivanja ozljede.
The method according to claim 1, wherein the coils are arranged about vertical and about parallel to each other. 
Postupak prema zahtjevu 1, naznačen time, da su spirale razmještene uspravno i paralelno jedna prema drugoj.
a cyclohexyl group substituted by 1 to 2 substituents independently selected from a hydroxy group or an amino group, or 
R* predstavlja (i) cikloheksilnu skupinu, supstituiranu s 1 do 2 supstituenta, koje se neovisno bira između hidroksi skupine ili amino skupine, ili
BACKGROUND OF THE INVENTION PDE4 inhibitors and antimuscarinic agents, in particular antagonists of M3 muscarinic receptors, are two classes of drugs useful in the treatment of respiratory disorders such as, asthma or Chronic Obstructive Pulmonary Diseases (COPD). 
Kortikosteroidi i antimuškarinski lijekovi, osobito antagonisti M3 muskarinskih receptora, predstavljaju dva razreda lijekova koji su korisni u liječenju respiratornih poremećaja, poput astme ili kronične opstruktivne plućne bolesti (KOPD). lako kortikosteroidi i antimuskarinski lijekovi mogu predstavljati učinkovite terapije, postoji klinička potreba za terapijama u liječenju astme i KOPD s potentnim i selektivnim djelovanjem i povoljnim profilom djelovanja.
A pharmaceutical composition comprising the Febuxostat crystalline form of claim 7 and at least one pharmaceutically acceptable excipient. 
Postupak priprave farmaceutske formulacije, naznačen time što se sastoji u kombiniranju kristalnog oblika febuksostata u skladu s bilo kojim od patentnih zahtjeva 1-9, s najmanje jednom farmaceutski prihvatljivom pomoćnom tvari.
culturing, in suspension in a serum-free medium, HEK293T cells transfected with at least one plasmid adapted for the production of a lentiviral vector, the culture being carried out in a volume of at least 50 L; 
- uzgoju, u suspenziji u mediju koji ne sadrži serum, stanica HEK293T transficiranih najmanje jednim plazmidom prilagođenim za proizvodnju lentivirusnog vektora, gdje se uzgoj provodi u volumenu od najmanje 50 1;
The method according to claim 4, wherein the quantification of the level of IGFBP2 protein is performed by capillary electrophoresis-mass spectroscopy technique (CE-MS). 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se kvantificiranje razine proteina IGFBP2 provodi tehnikom kapilarne elektroforeze spregnute s masenom spektroskopijom (CE-MS).
A compound of claim 4, which is or a pharmaceutically acceptable salt thereof. 
[image] [image] [image] ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih.
DP ranging from 10 up to 60, prebiotic fibres assures that a selective energy source is available for beneficial bacteria along the colon, from the beginning to the end. 
onih s DP-om od 10 do 60, probiotička vlakna osiguravaju selektivni izvor energije za korisne bakterije u debelom crijevu, od njegova početka do kraja.
The composition of claim 1, comprising baclofen and acamprosate or pharmaceutically acceptable salts thereof, as the only active agents. 
Smjesa za uporabu prema zahtjevu 1, sadrži baklofen i akamprozat kao jedine djelatne tvari.
performing intra prediction or inter prediction using the at least one prediction unit to generate a predictor, and reconstructing the coding unit using the residuals and the predictor, 
Uređaj za kodiranje slike, te uređaj sadrži: memoriju koja pohranjuje tok bitova; i najmanje jedan procesor konfiguriran za:
a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220 (L17); 
210 (H44) 1 varijabilnu regiju lakog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 220 (L17) (H44L17);
The solution was then allowed to cool to room temperature. 
Otopina je ostavljena da se ohladi do sobne temperature.
heating each of the intimate mixtures while recording the DSC dissolution endotherm of the mixture and determining Tend of each of the intimate mixtures, 
zagrijavanje svake bliske smjese uz bilježenje DSC endoterme otapanja smjese i utvrđivanje Tend svake bliske smjese,
An outer end of this strip 53 is also trapped in the neck 15 of the balloon 10 and has an arrow head shape enlargement 57 at said outer end, which cannot readily pass through the neck opening. 
Balon za zabave u skladu s patentnim zahijevom 1, naznačen time što vanjski krajnji predio (57) trake od izolacijskog materijala (53), koji ima povećanu širinu, ima proširenje koje ima oblik strelice.
The rotating machine according to claim 15, wherein the machine is a two-stroke motor comprising two mechanisms (1), wherein the first two eccentric elements (14) are placed at half-turn intervals, and wherein the second two eccentric elements (24) are placed at half-turn intervals. 
Rotacijski stroj prema jednom od patentnih zahtjeva od 15 do 17, naznačen time da je stroj dvotaktni motor s dva mehanizma (1), time da su prva dva ekscentrična elementa (14) poredana s odstupanjem od pola okreta te time da su druga dva ekscentrična elementa (24) poredana s odstupanjem od pola okreta.
The vaccine composition of claim 4, wherein said alkyl-PAA adjuvant is selected from the group consisting of decyl-PAA, octyl-PAA, butyl-PAA and methyl-PAA. 
Cjepivni pripravak u skladu s patentnim zahtjevom 4, naznačen time što se navedeni alkil-PAA adjuvans bira iz skupine koju čine decil-PAA, oktil-PAA, butil-PAA i metil-PAA.
A compound according to claim 3 wherein the ring is a spiro-cyclopropyl ring substituted with R7'a wherein; 
Spoj u skladu sa zahtjevom 3, naznačen time, da prsten je spiro-ciklopropil prsten supstituiran s R7'a gdje:
The process according to any one of claims 1 to 9, characterized in that the aqueous suspension of dispersed calcium carbonate comprises at least one dispersing agent, preferably a dispersing agent being selected from the group consisting of an organic dispersing agent, an inorganic dispersing agent and mixtures thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 9, naznačen time što vodena suspenzija disperznog kalcijevog karbonata sadrži barem jedno disperzno sredstvo koje se izabire iz grupe koja obuhvaća organsko disperzno sredstvo, anorgansko disperzno sredstvo i njihove mješavine.
The soft chewable veterinary composition of claim 5, wherein the binder is polyvinylpyrrolidone, a co-polymer of vinyl acetate and vinylpyrrolidone, or a polyethylene glycol, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje prema zahtjevu 5, naznačen time, da vezivo je polivinilpirolidon, kopolimer vinilacetata i vinilpirolidona, ili polietilen-glikol, ili njihove kombinacije.
is hydrogen or methyl; Ra and Rb are independently hydrogen or C1-3alkyl; or, when Ra and Rb are each other than hydrogen, Ra and Rb are optionally taken together with the nitrogen atom to which they are both attached to form a five to seven membered monocyclic ring; 
ili kada Ra i Rb nisu vodik, Ra i Rb su proizvoljno uzeti zajedno sa dušikom za koji su oba vezani da formiraju peto- do osmo-člani monociklični prsten; i L je izabran iz grupe koju čine O, S i N (Rd); gdje Rd predstavlja vodik, C1-6 alkil, ili aril.
the compound e.g. vildagliptin is present in an amount from 20% to 30% by weight; 
(a) vildagliptin, ili odgovarajuća količina bilo koje od njegovih soli, je prisutan količinom od 15% do 35% mase;
The process of paragraph 57, wherein Compound 6 is prepared by a process comprising: 
Postupak u skladu s patentnim zahtjevom 47, naznačen time što Spoj 6 se dobiva postupkom koji se sastoji u:
A process as claimed in claim 9 further comprising transferring the heated liquid to a buffer tank prior to delivery to the radiator element. 
Postupak prema zahtjevima 5 do 7 gdje se zagrijana tekućina prenosi u međuspremnik prije dopremanja do radijatora.
9341 Provimi Kliba, Switzerland) and tap water. 
9341 Provimi Kliba, Switzerland) i tekućoj vodi.
culturing a liver epithelial stem cell in contact with an extracellular matrix in the presence of an expansion medium, the medium comprising a basal medium for animal or human cells to which is added: epidermal growth factor (EGF), a Wnt agonist, a fibroblast growth factor (FGF) and/or hepatocyte growth factor (HGF) and Nicotinamide. 
uzgoj jedne ili više epitelijalne matične stanice jetre u kulturi, ili fragmenta jetre ili jetrenog žučnog kanala, u kontaktu sa izvanstaničnim matriksom u prisustvu medija za ekspanziju, gdje medij obuhvaća osnovni medij za životinjske ili humane stanice u koji se dodaje:
The conjugate of claim 5 having Formula 4 wherein n is an integer in the range of about 375 to 525 and -SR is the polypeptide (E10C)hPYY3-38 in which the S is the sulfur atom of the cysteine thiol group. 
SR đ gdje n je cijeli broj u rasponu od otprilike 375 do 525, a -SR je polipeptid (E10C)hPYY_2g, gdje S je atom sumpora u cisteinskoj tiolnoj skupini. 8.
The anti-FGFR3 antagonist antibody of any of the preceding paras, wherein a bivalent form of the antibody does not possess substantial agonist function. 
Anti-FGFR3 antagonističko protutijelo iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu protutijelo ne inducira značajnu deregulaciju FGFR3-a 1/ili bivalentni oblik protutijela nema značajnu agonističku funkciju.
reducing Compound 3 to yield Compound 4: reacting Compound 4 with Compound 6: 
(c) reakciji Spoja 4 sa Spojem 6: kako bi se dobilo Spoj 2, gdje:
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 a). 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
The method of claim 5 wherein each of the first and second mirror plugs further comprises a set of mirror plug coils (444) wrapped around a constriction (442) in the passageway between each of the first and second formation sections and the first and second divertors. 
Sustav prema zahtjevu 6, naznačen time, da zrcalni utikač dodatno obuhvaća komplet zrcalnih zavojnica omotanih oko tjesnaca (442) u prolaznom kanalu između svakog od prvog i drugog tvorbenog dijela (200) i prvog i drugog preusmjerivača (300).
The beverage dispensing assembly according to claim 10, wherein the resilient support means are provided in the base unit extending axially downward therefrom. 
Sklop za točenje pića prema zahtjevu 10, naznačen time, da su elastična potporna sredstva (18) predviđena u osnovnoj jedinici (3) i ta se sredstva protežu od nje aksijalno prema dolje.
The floating platform according to claim 7, wherein the electrically transmitted rotating means comprise a swivel connector positioned on the buoy or on the platform itself and a cable coming from the seabed and reaching the platform itself. 
Plutajuća platforma prema patentnom zahtjevu 7, naznačena time što rotirajuće sredstvo za električni prijenos sadrži okretni konektor (10) postavljen na plovak (8) ili na samu platformu i kabel (11) koji dolazi sa morskog dna i doseže do same platforme.
The solids were dissolved in 8:2 heptane/IPAc (250mL) and filtered to remove solids that would not dissolve. 
Krutine su bile otopljene u 8:2 heptanu/IPAc (250 mL) i filtrirane da bi se uklonile neotopljene krutine.